Chronic myeloid leukemia (CML) is characterized by the uncontrolled proliferation of hematopoietic cells carrying the Philadelphia chromosome (Ph), the product of reciprocal translocation between chromosomes 9 and 22, t(9;22)(q34.1;q11.2). Its molecular counterpart, the resultant BCR-ABL fusion gene, encodes a constitutively active form of the ABL tyrosine kinase (TK) that induces malignancy through the activation of multiple signal transduction pathways involved in hematopoietic cell growth and survival.
22, t(9;22)(q34.1;q11.2). Its molecular counterpart, the resultant BCR-ABL fusion gene, encodes a constitutively active form of the ABL tyrosine kinase (TK) that induces malignancy through the activation of multiple signal transduction pathways involved in hematopoietic cell growth and survival.
Understanding of the disease pathogenesis made it possible to develop molecularly targeted therapies. One such targeted therapy, imatinib mesylate (Gleevec ® , Novartis), was found to be a relatively specific inhibitor of the BCR-ABL TK and effective in blocking the molecular signals contributing to the CML phenotype. Imatinib binds the ABL domain at the ATP-binding site and traps the protein in an inactive conformation to inhibit the kinase activity. Its favorable pharmacokinetic and toxicity profile, paired with its excellent clinical results, rapidly made imatinib the standard frontline therapy for all chronic-phase CML patients.
Evolution of Treatment Regimens
For many years, patients with CML relied on agents such as hydroxyurea and busulfan to improve their quality of life. Later, survival prolongation was achieved through recombinant interferon-alpha alone or in combination with cytarabine and, in some patients, allogeneic stem cell transplants. 1, 2 In the International Randomized Study of Interferon and STI571 (IRIS), imatinib was found to be superior to interferon-alpha as initial therapy for patients in the early chronic phase. After five years of follow-up, imatinib has resulted in a complete cytogenetic response (CCyR) rate of 82% and a projected rate of death or progression to accelerated-or blastic-phase CML of 7%. 2, 3 Six-year follow-up data for imatinib use in the IRIS study continue to provide clear evidence of durable responses, with a 0% rate of transformation to accelerated-phase CML or blast crisis between years five and six, and an overall estimated six-year survival rate of 88%. 4 Imatinib (400mg/day) is now considered by both the US National Comprehensive
Cancer Network (NCCN) and the European LeukemiaNet to be the standard approach for the initial treatment of chronic-phase CML. 5, 6 However, the development of imatinib resistance has been reported in some patients, with both primary resistance (failure to achieve a desired response at specific times) and secondary resistance (loss of response) reported in a subset of patients. Primary hematological resistance occurs rarely, affecting 
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Dasatinib in Imatinib Failure
Dasatinib is a highly potent multitarget inhibitor of the BCR-ABL kinase and Table 1 . The proportion of patients remaining progressionfree at two years when treated with dasatinib after resistance or intolerance to imatinib was reported at 80%, with 94% overall survival.
The trial data show that dasatinib is generally well-tolerated, with thrombocytopenia and neutropenia as the most common grade 3-4 adverse effects. 16 While the incidence of grade 3-4 neutropenia and thrombocytopenia are 49 and 48%, respectively, in chronic-phase CML, 17 the rates increase as the leukemia progresses, reaching 76 and 82% in accelerated phase 12 and ranges of 79-82% and 84-88% in blast crisis.
Dasatinib is currently US Food and Drug Administration (FDA)-approved for treating all phases of Ph+ CML following imatinib resistance or toxicity, as well as for Ph+ acute lymphoblastic leukemia (ALL) with resistance or intolerance to prior therapy. Subsequent studies have shown that in the chronic phase, a dose of 100mg once daily is as effective as the initially used dose of 70mg BID, but is associated with significantly fewer grade 3-4 adverse events, particularly myelosuppression and pleural effusion, compared with combined adverse events for 50mg BID, 70mg BID, and 140mg once daily. 18 Thus, 100mg once daily has become the standard dose in chronic-phase CML.
Nilotinib in Imatinib Failure
Derived from imatinib, nilotinib has a much higher binding affinity and selectivity for the inactive conformation of ABL kinase. Nilotinib's inhibitory activity is 20-to 50-fold stronger than that of imatinib in imatinib-sensitive cell lines, and three-to seven-fold stronger in imatinib-resistant cell lines. 11, 19, 20 A phase I dose-escalation trial demonstrated that 400-600mg nilotinib BID
was well-tolerated and demonstrated anti-CML activity. 21 This was followed by the phase II trial investigating nilotinib 400mg BID orally in patients with all phases of CML who had experienced imatinib failure. Nilotinib was found to be effective in inducing hematological and cytogenetic responses; the data from a two-year follow-up are summarized in Table 2 . Under nilotinib therapy, 76.2% of chronic-phase CML patients achieved complete hematological response (CHR) in one month and 40.0% achieved CCyR. Among the patients who achieved major CHR, 84% maintained responsiveness for at least 18 months, with 64% of these responders progression-free. The 18-month survival rate is an estimated 91%. Thrombocytopenia and neutropenia were reported as the most common grade 3-4 adverse effects. 17 Although patients with accelerated-phase CML had similar toxicities to those in the chronicphase study, 22, 23 patients in blast-phase CML experienced higher rates of adverse effects: neutropenia (67%), thrombocytopenia (62%), and anemia (42%). 24 In October 2007, nilotinib was granted accelerated approval by the FDA for the treatment of chronic and accelerated phases of Ph+ CML in patients resistant or intolerant to prior imatinib therapy.
Adverse Events Associated with Second-generation ABL Kinase Inhibitors
The toxicity profiles of dasatinib and nilotinib are different. Myelosuppression (particularly grade 3-4 neutropenia and thrombocytopenia) occurs more frequently with dasatinib (70mg BID) than with nilotinib (see Table 3 ).
Biochemical abnormalities were observed as well, including elevated lipase levels in 15% and bilirubin in 8% of nilotinib patients, and hypophosphatemia in 10-15% of patients with either nilotinib or dasatinib. Fluid retention occurs more frequently with dasatinib, particularly pleural effusions; these have been reported in 27% of patients, although in most instances they are mild. The reported rate of grade 3-4 effusions is only 9%. 16, 17 These agents both have the potential to prolong the QT interval, thus they are not recommended in patients with long QT syndrome, and patients with hypokalemia or hypomagnesemia should have these abnormalities corrected before the start of therapy. Chronic administration of dasatinib caused mean changes of QTcF of 3-6msec (upper 95% confidence interval [CI] <8msec). 25 Maximum mean placebo-adjusted QTcF change from baseline was determined to be 18msec
(one-sided 95% upper CI 26msec). 26 Nilotinib has been associated with a time-averaged mean change from baseline QTcF of 5msec. 
Mutation Dynamics in Sequential Inhibitor Treatments
With the notable exception of the T315I mutation in the BCR-ABL kinase T315A). However, mutations developing after exposure to nilotinib or dasatinib appear to occur at a lower rate than those associated with imatinib. Because 
T315I is resistant to imatinib, dasatinib, and nilotinib, there was concern that using the second-generation TKIs would select for this mutation, but interestingly enough there was no marked increase in T315I development. 31 The data on the efficacy and safety of sequential TKI therapy remain limited.
Nilotinib administered to CML patients of all phases who have failed both imatinib and dasatinib therapy has shown significant hematological and cytogenetic responses. 35 Similarly, dasatinib can induce hematological and cytogenetic responses in patients who have failed both imatinib and nilotinib. 36 Knowledge of specific mutations may sometimes guide therapy, as a mutation that might be relatively insensitive to one agent may respond well to the alternative agent. 37 Currently, the NCCN recommends mutational analysis in cases of rising bcr-abl levels in order to provide additional information relating to the possible emergence of an abl mutation. These new drugs have expanded our CML options, and hopefully the currently ongoing phase II studies will tell us which drug is the best choice for the patient. ■ 
